Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:1121-1127
Published online before print August 23, 2004, doi: 10.1161/01.CIR.0000139884.81390.56
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/9/1121    most recent
01.CIR.0000139884.81390.56v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirchmair, R.
Right arrow Articles by Schratzberger, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirchmair, R.
Right arrow Articles by Schratzberger, P.
Related Collections
Right arrow Angiogenesis

(Circulation. 2004;110:1121-1127.)
© 2004 American Heart Association, Inc.


Original Articles

Secretoneurin, an Angiogenic Neuropeptide, Induces Postnatal Vasculogenesis

Rudolf Kirchmair, MD; Margot Egger; Dirk H. Walter, MD; Wolfgang Eisterer, MD; Andreas Niederwanger, MD; Ewald Woell, MD; Markus Nagl, MD; Michael Pedrini, MD; Toshinori Murayama, MD PhD; Silke Frauscher; Allison Hanley; Marcy Silver; Marianne Brodmann, MD; Wolfgang Sturm, MD; Reiner Fischer-Colbrie, PhD; Douglas W. Losordo, MD; Josef R. Patsch, MD; Peter Schratzberger, MD

From the Clinical Department of Internal Medicine, Clinical Division of General Internal Medicine (R.K., M.E., W.E., A.N., E.W., M.P., S.F., W.S., J.R.P., P.S.), Department of Pharmacology (R.F.-C.), and Institute of Hygiene and Social Medicine (M.N.), Innsbruck Medical University, Innsbruck, Austria; Department of Internal Medicine, Division of Angiology, University Graz, Graz, Austria (M.B.); and Division of Cardiovascular Research (D.H.W., T.M., A.H., M.S., D.W.L.) and Vascular Medicine (D.W.L.), St Elizabeth’s Medical Center–Tufts University School of Medicine, Boston, Mass.

Correspondence to Rudolf Kirchmair, MD, or Peter Schratzberger, MD, Clinical Department of Internal Medicine, Innsbruck Medical University, Anichstr. 35, 6020 Innsbruck, Austria. E-mail rudolf.kirchmair{at}uibk.ac.at or peter.schratzberger@uibk.ac.at

Received December 30, 2003; revision received April 6, 2004; accepted April 8, 2004.

Background— Induction of postnatal vasculogenesis, the mobilization of bone marrow–derived endothelial progenitor cells and incorporation of these cells into sites of blood vessel formation, is a well-known feature of angiogenic cytokines such as vascular endothelial growth factor. We hypothesized that the angiogenic neuropeptide secretoneurin induces this kind of neovascularization.

Methods and Results— Secretoneurin induced mobilization of endothelial progenitor cells to sites of vasculogenesis in vivo in the cornea neovascularization assay. Progenitor cells were incorporated into vascular structures or were located adjacent to them. Systemic injection of secretoneurin led to increase of circulating stem cells and endothelial progenitor cells. In vitro secretoneurin induced migration, exerted antiapoptotic effects, and increased the number of these cells. Furthermore, secretoneurin stimulated the mitogen-activated protein kinase system, as shown by phosphorylation of extracellular signal–regulated kinase, and activated the protein kinase B/Akt pathway. Activation of mitogen-activated protein kinase was necessary for increase of cell number and migration, whereas Akt seemed to play a role in migration of endothelial progenitor cells.

Conclusions— These data show that the angiogenic neuropeptide secretoneurin stimulates postnatal vasculogenesis by mobilization, migration, and incorporation of endothelial progenitor cells.


Key Words: angiogenesis • endothelium • nervous system




This article has been cited by other articles:


Home page
Circ. Res.Home page
W. Schgoer, M. Theurl, J. Jeschke, A. G.E. Beer, K. Albrecht, R. Gander, S. Rong, D. Vasiljevic, M. Egger, A. M. Wolf, et al.
Gene Therapy With the Angiogenic Cytokine Secretoneurin Induces Therapeutic Angiogenesis by a Nitric Oxide-Dependent Mechanism
Circ. Res., November 6, 2009; 105(10): 994 - 1002.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. Egger, W. Schgoer, A. G. E. Beer, J. Jeschke, J. Leierer, M. Theurl, S. Frauscher, O. M. Tepper, A. Niederwanger, A. Ritsch, et al.
Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1{alpha}- and basic FGF-dependent pathway in muscle cells
FASEB J, September 1, 2007; 21(11): 2906 - 2917.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
G. Wen, J. Wessel, W. Zhou, G. B. Ehret, F. Rao, M. Stridsberg, S. K. Mahata, P. M. Gent, M. Das, R. S. Cooper, et al.
An ancestral variant of Secretogranin II confers regulation by PHOX2 transcription factors and association with hypertension
Hum. Mol. Genet., July 15, 2007; 16(14): 1752 - 1764.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
T. D. Veenstra, T. P. Conrads, B. L. Hood, A. M. Avellino, R. G. Ellenbogen, and R. S. Morrison
Biomarkers: Mining the Biofluid Proteome
Mol. Cell. Proteomics, April 1, 2005; 4(4): 409 - 418.
[Abstract] [Full Text] [PDF]